Teva Pharmaceutical Industries Limited (NYSE:TEVA) was downgraded by equities researchers at BidaskClub from a “sell” rating to a “strong sell” rating in a report issued on Wednesday.

Other equities analysts also recently issued reports about the stock. Citigroup Inc. downgraded shares of Teva Pharmaceutical Industries Limited from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $32.00 to $19.00 in a report on Wednesday. Zacks Investment Research downgraded shares of Teva Pharmaceutical Industries Limited from a “hold” rating to a “strong sell” rating in a report on Wednesday, August 9th. Deutsche Bank AG reaffirmed a “buy” rating and set a $28.00 price objective (down from $43.00) on shares of Teva Pharmaceutical Industries Limited in a report on Wednesday, August 9th. Jefferies Group LLC reaffirmed a “hold” rating and set a $26.00 price objective (down from $33.00) on shares of Teva Pharmaceutical Industries Limited in a report on Wednesday, August 9th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and set a $27.00 price objective (down from $31.00) on shares of Teva Pharmaceutical Industries Limited in a report on Wednesday, August 9th. Three analysts have rated the stock with a sell rating, twenty have issued a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $36.73.

Shares of Teva Pharmaceutical Industries Limited (TEVA) traded down 0.50% on Wednesday, hitting $17.88. 8,824,316 shares of the stock traded hands. The company’s market cap is $18.17 billion. The stock has a 50 day moving average of $28.78 and a 200 day moving average of $31.30. Teva Pharmaceutical Industries Limited has a one year low of $16.81 and a one year high of $53.96.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last announced its quarterly earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.06 by $0.07. Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. The firm had revenue of $5.69 billion for the quarter, compared to analysts’ expectations of $5.72 billion. During the same period last year, the company posted $1.25 earnings per share. The business’s quarterly revenue was up 12.9% on a year-over-year basis. Equities analysts anticipate that Teva Pharmaceutical Industries Limited will post $4.32 earnings per share for the current year.

WARNING: “Teva Pharmaceutical Industries Limited (TEVA) Lowered to Strong Sell at BidaskClub” was published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/08/16/teva-pharmaceutical-industries-limited-teva-lowered-to-strong-sell-at-bidaskclub.html.

Several large investors have recently made changes to their positions in TEVA. Paulson & CO. Inc. bought a new stake in shares of Teva Pharmaceutical Industries Limited during the fourth quarter worth $577,310,000. Norges Bank bought a new stake in shares of Teva Pharmaceutical Industries Limited during the fourth quarter worth $495,909,000. Barrow Hanley Mewhinney & Strauss LLC boosted its stake in shares of Teva Pharmaceutical Industries Limited by 143.7% in the second quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 22,700,812 shares of the company’s stock worth $1,140,263,000 after buying an additional 13,385,352 shares in the last quarter. Franklin Resources Inc. boosted its stake in shares of Teva Pharmaceutical Industries Limited by 20.9% in the fourth quarter. Franklin Resources Inc. now owns 56,635,303 shares of the company’s stock worth $2,052,926,000 after buying an additional 9,775,505 shares in the last quarter. Finally, Capital Research Global Investors boosted its stake in shares of Teva Pharmaceutical Industries Limited by 13.8% in the second quarter. Capital Research Global Investors now owns 76,325,059 shares of the company’s stock worth $2,535,518,000 after buying an additional 9,260,426 shares in the last quarter. Institutional investors and hedge funds own 56.04% of the company’s stock.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.